drugset / Trial / NCT03763149
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignancies.
Timeline
- Start
- 2019-02-19
- Primary completion
- 2021-03-29
- Completion
- 2021-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI188 | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | IBI188 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | IBI188 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | IBI188 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | IBI188 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | IBI188 | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | IBI188 | Monoclonal antibody | 30 mg/kg | Intravenous |